Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation

Patent metadata

Field	Value
Publication number	US-11517879-B2
Application number	US-202017107600-A
Country	US
Kind code	B2
Filing date	Nov 30, 2020
Priority date	Sep 29, 2006
Publication date	Dec 6, 2022
Grant date	Dec 6, 2022

Abstract

The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

First claim

What is claimed is:

1. A separation matrix comprising a plurality of chromatography ligands coupled to a solid support,
wherein the ligand comprises one or more mutated Domain C of Staphylococcus protein A (SpA) which has a sequence that is at least 77% identical to the amino acid sequence shown in SEQ ID NO:2.

2. The separation matrix of claim 1 , wherein the ligand is capable of binding to the Fab part of an antibody.

3. The separation matrix of claim 1 , wherein the ligand comprises one or more mutated Domain C of Staphylococcus protein A (SpA) which has a sequence that is at least 98% identical to the amino acid sequence shown in SEQ ID NO: 2.

4. The separation matrix of claim 1 , wherein the one or more mutated Domain C of Staphylococcus protein A (SpA) comprises SEQ ID NO: 2 with mutation G25A.

5. The separation matrix of claim 1 , wherein at least one asparagine in the sequence of the ligand is replaced with an amino acid other than glutamine or aspartic acid.

6. The separation matrix of claim 1 , wherein the ligand comprises a terminal coupling group comprising at least one nitrogen and/or sulphur atom(s).

7. The separation matrix of claim 6 , wherein the terminal group comprises arginine or cysteine.

8. The separation matrix of claim 1 , wherein the ligand is coupled to the solid support via thioether bonds.

9. The separation matrix of claim 1 , wherein the ligand is multimeric and comprises at least two Domain C mutants.

10. The separation matrix of claim 9 , wherein the multimeric ligand comprises one or more other alkaline-stable protein-based units.

11. The separation matrix of claim 9 , wherein the multimeric ligand comprises 2-8 Domain C units, optionally coupled via linker segments.

12. The separation matrix of claim 1 , wherein the solid support is a polysaccharide.

13. The separation matrix of claim 1 , wherein the solid support is comprised of substantially spherical particles.

14. The separation matrix of claim 1 , wherein the solid support is porous.

Assignees

• Cytiva Bioprocess R & D Ab

Inventors

• Hall Martin
• Larsson Sture
• Muranyi Andreas
• Rodrigo Gustav
• Zou Jinyu
• Aberg Per-Mikael

Classifications

• B01J2220/52

  Sorbents specially adapted for preparative chromatography · CPC title

• B01J20/285

  based on polymers · CPC title

• B01J20/3293

  Coatings on a core, the core being particle or fiber shaped, e.g. encapsulated particles, coated fibers · CPC title

• B01D15/3809 Primary

  of the antigen-antibody type, e.g. protein A, G or L chromatography · CPC title

• C07K1/22

  Affinity chromatography or related techniques based upon selective absorption processes · CPC title